Long-standing COVID-19 infection outcomes like cognitive & functional, and acute neurological complexities are less discussed, presented, and documented substantially.
It includes breathing & gastrointestinal difficulties, sleep disturbances, frequent headaches, anxiety episodes, depressed feelings, attention impairment & loss of memory.
In inappropriately handled long-lasting hospitalized patients warning consequences of chronic stage causes mental challenges & “brain fog”.
Long COVID care demands the development of patient-centered preventive measures, rehabilitation techniques & clinical management procedures. Simultaneously detailed analysis and understanding of the prevalence, risk factors, and pathophysiology of brain fog is crucial.
In post-acute sequelae, COVID-19 patients, structural & functional abnormalities of frontal, temporal, and limbic areas develop.
Olfactory network structural changes including prefrontal structures, corpus callosum and insula involvement, temporal lobe, basal ganglia, brainstem, and cerebellum are the most reported.
The cognitive disturbance duration depends on the severity of cognitive damage.
Brain fog is a descriptive terminology & is explained by the patients as a diverse bunch of intellectual function-related complications comprising trouble in thinking, remembering, and reasoning that interferes with daily functioning and instigates neuropsychological dysfunctions.
As per the World Health Organization (WHO), brain fog is defined as an informal term for a common complaint of intellectual functions among patients with post-acute COVID-19. Impairment of cognitive function, confusion, short-term memory loss, dizziness, and inability to concentrate come under brain fog.
It is a common characteristic in healing or recovering patients affecting their higher cognitive or “executive” function.
Brain fog requires serious attention from medical practitioners in employing its instructive & protective procedures.
Virus-induced long-standing & neurodegeneration cognitive impairment denotes the hippocampal distribution of microglial activation, systemic inflammation & sepsis.
Severe acute intensive care patients of COVID-19 develop hypoxia, vascular nerve cell injury & endothelial dysfunction associated with microvascular damage. Concomitantly immunological dysregulation, chronic inflammation & peripheral organ dysfunction occur. Cerebral white matter becomes vulnerable to ischaemic injury, cerebral hypoperfusion, amyloid-beta rapid accumulation, and TAR DNA binding protein-43 pathology.
There are also chances of systemic inflammatory injury & abnormalities, blood-brain barrier permeability increase & disturbance in tight junction proteins associated with brain parenchyma.
Cognition controlling the hippocampus, temporal lobe, and thalamus gets affected by thrombotic and inflammatory cascade leading to capillary occlusion, and ischemia.
Suitable intervention strategies, scientific community-based future studies & trials can reduce long-lasting COVID-19-related cognitive diminishing symptoms & their effects.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation